Apomorphine hydrochloride

CLINICAL USE

Treatment of refractory motor fluctuations in
Parkinson’s disease

DOSE IN NORMAL RENAL FUNCTION

3–30 mg daily in divided doses (maximum
single dose 10 mg); infusion: 1–4 mg/hour
during waking hours
Maximum dose 100 mg daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
312.8

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
90

%Excreted unchanged in urine &nbsp &nbsp :
<2

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :
2–19

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :
29.1–36.9 minutes

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function.
Start with 1 mg

10 to 20 &nbsp &nbsp : Dose as in normal renal function.
Start with 1 mg

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. Start with 1 mg

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
Unlikely to be dialysed. Dose as in
GFR <10 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
Unlikely to be dialysed. Dose as in
GFR <10 mL/min

HDF/high flux &nbsp :
Unlikely to be dialysed. Dose as in
GFR <10 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:
Unlikely to be dialysed. Dose as in
GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Nitrates: enhanced hypotensive effect

Antihypertensives: enhanced hypotensive

effect

ADMINISTRATION

Reconstition

–

Route

Rate of Administration

1–4 mg/hour

Comments

Change site every 4 hours for SC

administration

OTHER INFORMATION

Pre-treatment with domperidone is

required for at least 2 days before and at
least 3 days after treatment

Bioavailability by subcutaneous

administration is 17–18%

Most of dose is excreted in the urine as

active metabolites

Tags: post-by-auto-php